BIO-THERA Bio-Pharmaceutical Co., Ltd (Stock Code: 688177) has recently received a Notice of Approval of Drug Clinical Trial approved by the State Drug Administration for the Company's investigational product BAT7205 for injection.

BAT7205 is a PD-L1/IL-15 bifunctional antibody fusion protein developed by BIO-THERA and is intended to be developed for the treatment of locally advanced or metastatic solid tumors.IL-15 is a pleiotropic cytokine that is essential for the regulation of many immune functions, particularly the development, proliferation and activation of CD8+ memory T cells and NK cells, and promotes PD-1 inhibitor-naïve CD8 + activation and proliferation of tumor-infiltrating T cells, which is expected to significantly improve the clinical efficacy of PD-1/PD-L1 analogs.

BAT7205 consists of recombinant humanized anti-PD-L1 antibody and IL-15/IL-15Rαsushi fusion protein, which can both block the PD-1/PD-L1 immunosuppressive pathway and activate the immune cells through IL-15, thus achieving the synergistic effect of deregulation of immunosuppression and activation of immune anti-tumor. In addition, PD-L1 antibody can target IL-15 to PD-L1+ tumor microenvironment and selectively activate tumor-infiltrating CD8+ T cells and NK cells, which can reduce the systemic side effects of IL-15; the fusion with PD-L1 antibody can also significantly prolong the half-life of IL-15 in vivo, which can make it have a more durable biological function. BAT7205, as the first bifunctional antibody fusion protein independently developed by the company, is another important symbol of the company's innovative drug development in the field of oncology.

https://mp.weixin.qq.com/s/WIPHWZeONo2Z2syJSfOuzA